Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (2010−2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.

• Section 1: Drug discovery techniques and Strategies1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application3. Hit Discovery from DNA-Encoded Chemical Libraries4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy5. Macrocyclization strategy in kinase drug discovery6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments8. A future battle, small molecule drugs for cancer stem cell targeted therapy9. Stem cell therapies for combating emerging and re-emerging viral infections10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?12. Selenium and small molecules: a symbiotic partnership13. Novel Combinations of CD33-Targeted Immunotherapies14. Novel payloads of antibody–drug conjugates15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines16. mRNA Vaccines: The Next Frontier in Disease Prevention17. Unravelling the drying techniques of protein biopharmaceuticalsSection 2: Drug discovery case studies18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-1920. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (2010−2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.

• Section 1: Drug discovery techniques and Strategies1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application3. Hit Discovery from DNA-Encoded Chemical Libraries4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy5. Macrocyclization strategy in kinase drug discovery6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments8. A future battle, small molecule drugs for cancer stem cell targeted therapy9. Stem cell therapies for combating emerging and re-emerging viral infections10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?12. Selenium and small molecules: a symbiotic partnership13. Novel Combinations of CD33-Targeted Immunotherapies14. Novel payloads of antibody–drug conjugates15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines16. mRNA Vaccines: The Next Frontier in Disease Prevention17. Unravelling the drying techniques of protein biopharmaceuticalsSection 2: Drug discovery case studies18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-1920. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. He then earned his M.S. and Ph.D. degrees in medicinal chemistry from Shandong University in 2008 and 2010. He subsequently joined Shandong University as a Lecturer (2010−2012). From 2012 to 2014, he worked as a postdoctoral fellow funded by Japan Society for the Promotion of Science. He is currently a full professor in the Department of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel anti-viral (HIV, HBV, influenza, coronavirus, etc.), anti-gout, and anti-cancer agents based on rational drug design and combinatorial chemistry approaches. He also co-edited six books published by People's Medical Publishing House and Springer Nature, respectively and granted 50 patents (30 of them licensed). He currently serves as advisory editorial board member of Journal of Medicinal Chemistry.

• Section 1: Drug discovery techniques and Strategies1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application3. Hit Discovery from DNA-Encoded Chemical Libraries4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy5. Macrocyclization strategy in kinase drug discovery6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments8. A future battle, small molecule drugs for cancer stem cell targeted therapy9. Stem cell therapies for combating emerging and re-emerging viral infections10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role?12. Selenium and small molecules: a symbiotic partnership13. Novel Combinations of CD33-Targeted Immunotherapies14. Novel payloads of antibody–drug conjugates15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines16. mRNA Vaccines: The Next Frontier in Disease Prevention17. Unravelling the drying techniques of protein biopharmaceuticalsSection 2: Drug discovery case studies18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-1920. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis30. Oliceridine (TRV-130): A Biased Agonist of the μ Opioid Receptor as a Novel Analgesic31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin33. Antidiabetic Drugs Targeted PPARγ: From Full Agonists to Selective Modulators34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease